{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:27:51Z","timestamp":1773923271135,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18fk0210001h0003"],"award-info":[{"award-number":["JP18fk0210001h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K15960"],"award-info":[{"award-number":["17K15960"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00535-018-1526-3","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T04:45:11Z","timestamp":1540961111000},"page":"339-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy"],"prefix":"10.1007","volume":"54","author":[{"given":"Etsuko","family":"Iio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritomo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Itokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Takaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Senoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Hon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunori","family":"Kusakabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokatsu","family":"Miyaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Matsunami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"1526_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00535-016-1290-1","volume":"52","author":"E Ogawa","year":"2017","unstructured":"Ogawa E, Furusyo N, Nomura H, et al. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol. 2017;52:845\u201354.","journal-title":"J Gastroenterol"},{"key":"1526_CR2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/hepr.12898","volume":"47","author":"E Iio","year":"2017","unstructured":"Iio E, Shimada N, Takaguchi K, et al. Clinical evaluation of sofosbuvir\/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir\/asunaprevir therapy. Hepatol Res. 2017;47:1308\u201316.","journal-title":"Hepatol Res"},{"key":"1526_CR3","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67:1204\u201312.","journal-title":"J Hepatol"},{"key":"1526_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","volume":"68","author":"GN Ioannou","year":"2017","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;68:25\u201332.","journal-title":"J Hepatol"},{"key":"1526_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","volume":"67","author":"H Nagata","year":"2017","unstructured":"Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67:933\u20139.","journal-title":"J Hepatol"},{"key":"1526_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/hepr.12393","volume":"45","author":"N Hiramatsu","year":"2014","unstructured":"Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2014;45:152\u201361.","journal-title":"Hepatol Res"},{"key":"1526_CR7","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/cncr.20537","volume":"101","author":"A Makiyama","year":"2004","unstructured":"Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616\u201322.","journal-title":"Cancer"},{"key":"1526_CR8","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1093\/jac\/dks269","volume":"67","author":"KC Chang","year":"2012","unstructured":"Chang KC, Hung CH, Lu SN, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother. 2012;67:2766\u201372.","journal-title":"J Antimicrob Chemother"},{"key":"1526_CR9","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2169\/internalmedicine.52.1180","volume":"52","author":"A Sato","year":"2013","unstructured":"Sato A, Sata M, Ikeda K, et al. Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan. Intern Med. 2013;52:2701\u20136.","journal-title":"Intern Med"},{"key":"1526_CR10","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/hep.26087","volume":"57","author":"Y Arase","year":"2013","unstructured":"Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57:964\u201373.","journal-title":"Hepatology"},{"key":"1526_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.28535","volume":"64","author":"HB El-Serag","year":"2016","unstructured":"El-Serag HB, Kanwal F, Richardson P, et al. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016;64:130\u20137.","journal-title":"Hepatology"},{"key":"1526_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jhep.2012.10.017","volume":"58","author":"E Ogawa","year":"2013","unstructured":"Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol. 2013;58:495\u2013501.","journal-title":"J Hepatol"},{"key":"1526_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.26442","volume":"58","author":"Y Asahina","year":"2013","unstructured":"Asahina Y, Tsuchiya K, Nishimura T, et al. alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253\u201362.","journal-title":"Hepatology"},{"key":"1526_CR14","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.cgh.2013.11.033","volume":"12","author":"T Oze","year":"2014","unstructured":"Oze T, Hiramatsu N, Yakushijin T, et al. Post-treatment levels of alpha-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2014;12:1186\u201395.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1526_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jhep.2014.02.022","volume":"61","author":"CF Huang","year":"2014","unstructured":"Huang CF, Yeh ML, Tsai PC, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol. 2014;61:67\u201374.","journal-title":"J Hepatol"},{"key":"1526_CR16","doi-asserted-by":"publisher","first-page":"e4157","DOI":"10.1097\/MD.0000000000004157","volume":"95","author":"CF Huang","year":"2016","unstructured":"Huang CF, Yeh ML, Huang CY, et al. Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. Med (Baltimore). 2016;95:e4157.","journal-title":"Med (Baltimore)"},{"key":"1526_CR17","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/hep.21363","volume":"44","author":"ML Yu","year":"2006","unstructured":"Yu ML, Lin SM, Lee CM, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology. 2006;44:1086\u201397.","journal-title":"Hepatology"},{"key":"1526_CR18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2017.01.041","volume":"152","author":"K Matsuura","year":"2017","unstructured":"Matsuura K, Sawai H, Ikeo K, et al. Genome-wide association study identifies TLL1 variant associated with development of Hepatocellular Carcinoma after eradication of hepatitis C virus infection. Gastroenterology. 2017;152:1383\u201394.","journal-title":"Gastroenterology"},{"key":"1526_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13233","author":"Y Yasui","year":"2018","unstructured":"Yasui Y, Kurosaki M, Komiyama Y, et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after SVR by direct acting antivirals for HCV. Hepatol Res. 2018. \n                    https:\/\/doi.org\/10.1111\/hepr.13233\n                    \n                  .","journal-title":"Hepatol Res"},{"key":"1526_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"1526_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1526_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/jmv.24334","volume":"88","author":"K Matsuura","year":"2016","unstructured":"Matsuura K, Tanaka Y. Host genetic variants influencing the clinical course of hepatitis C virus infection. J Med Virol. 2016;88:185\u201395.","journal-title":"J Med Virol"},{"key":"1526_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/hepr.13042","volume":"48","author":"K Matsuura","year":"2018","unstructured":"Matsuura K, Tanaka Y. Host genetic variations associated with disease progression in chronic hepatitis C virus infection. Hepatol Res. 2018;48:127\u201333.","journal-title":"Hepatol Res"},{"issue":"1244\u201352","key":"1526_CR24","first-page":"e1","volume":"143","author":"E Patin","year":"2012","unstructured":"Patin E, Kutalik Z, Guergnon J, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology. 2012;143(1244\u201352):e1\u201312.","journal-title":"Gastroenterology"},{"key":"1526_CR25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jhep.2012.12.024","volume":"58","author":"Y Urabe","year":"2013","unstructured":"Urabe Y, Ochi H, Kato N, et al. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol. 2013;58:875\u201382.","journal-title":"J Hepatol"},{"key":"1526_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/ng.809","volume":"43","author":"V Kumar","year":"2011","unstructured":"Kumar V, Kato N, Urabe Y, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011;43:455\u20138.","journal-title":"Nat Genet"},{"key":"1526_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ng.876","volume":"43","author":"D Miki","year":"2011","unstructured":"Miki D, Ochi H, Hayes CN, et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet. 2011;43:797\u2013800.","journal-title":"Nat Genet"},{"key":"1526_CR28","doi-asserted-by":"publisher","first-page":"26372","DOI":"10.1074\/jbc.M203247200","volume":"277","author":"A Rattenholl","year":"2002","unstructured":"Rattenholl A, Pappano WN, Koch M, et al. Proteinases of the bone morphogenetic protein-1 family convert procollagen VII to mature anchoring fibril collagen. J Biol Chem. 2002;277:26372\u20138.","journal-title":"J Biol Chem"},{"key":"1526_CR29","doi-asserted-by":"publisher","first-page":"15661","DOI":"10.1074\/jbc.M210588200","volume":"278","author":"DP Veitch","year":"2003","unstructured":"Veitch DP, Nokelainen P, McGowan KA, et al. Mammalian tolloid metalloproteinase, and not matrix metalloprotease 2 or membrane type 1 metalloprotease, processes laminin-5 in keratinocytes and skin. J Biol Chem. 2003;278:15661\u20138.","journal-title":"J Biol Chem"},{"key":"1526_CR30","doi-asserted-by":"publisher","first-page":"41626","DOI":"10.1074\/jbc.M406630200","volume":"279","author":"G Ge","year":"2004","unstructured":"Ge G, Seo NS, Liang X, et al. Bone morphogenetic protein-1\/tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis. J Biol Chem. 2004;279:41626\u201333.","journal-title":"J Biol Chem"},{"key":"1526_CR31","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.1074\/jbc.M409841200","volume":"280","author":"EM Gonzalez","year":"2005","unstructured":"Gonzalez EM, Reed CC, Bix G, et al. BMP-1\/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J Biol Chem. 2005;280:7080\u20137.","journal-title":"J Biol Chem"},{"key":"1526_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1126\/science.271.5247.360","volume":"271","author":"E Kessler","year":"1996","unstructured":"Kessler E, Takahara K, Biniaminov L, et al. Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science. 1996;271:360\u20132.","journal-title":"Science"},{"key":"1526_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1083\/jcb.200606058","volume":"175","author":"G Ge","year":"2006","unstructured":"Ge G, Greenspan DS. BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. J Cell Biol. 2006;175:111\u201320.","journal-title":"J Cell Biol"},{"key":"1526_CR34","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/0016-5085(94)90824-9","volume":"107","author":"T Aihara","year":"1994","unstructured":"Aihara T, Noguchi S, Sasaki Y, et al. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology. 1994;107:1805\u201311.","journal-title":"Gastroenterology"},{"key":"1526_CR35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00535-017-1372-8","volume":"53","author":"Y Seko","year":"2018","unstructured":"Seko Y, Yamaguchi K, Mizuno N, et al. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. J Gastroenterol. 2018;53:438\u201348.","journal-title":"J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1526-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-018-1526-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1526-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T09:39:27Z","timestamp":1589449167000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-018-1526-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1526"],"URL":"https:\/\/doi.org\/10.1007\/s00535-018-1526-3","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]},"assertion":[{"value":"29 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yasuhito Tanaka is currently conducting research sponsored by Chugai Pharmaceutical Co., Ltd and has received honoraria from Janssen Pharmaceutical K.K, and Gilead Sciences. Masanori Atsukawa is currently conducting research sponsored by MSD K.K., and AbbVie Inc., and has received honoraria from MSD K.K. and Gilead Sciences. Koichi Takaguchi has received honoraria from Gilead Sciences, MSD K.K., AbbVie Inc., Bristol-Myers Squibb, and Astrazeneka KK. Hideyuki Nomura has received honoraria from Gilead Sciences. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}